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Cognition in chronic kidney disease:
a systematic review and meta-analysis
Israel Berger1* , Sunny Wu1, Philip Masson1, Patrick J. Kelly1, Fiona A. Duthie2, William Whiteley2, Daniel Parker3,
David Gillespie2 and Angela C. Webster1,4*
Abstract
Background: Cognitive impairment is common in people with chronic kidney disease (CKD) and associated with
increased morbidity and mortality. Subtle changes can impact engagement with healthcare, comprehension,
decision-making, and medication adherence. We aimed to systematically summarise evidence of cognitive
changes in CKD.
Methods: We searched MEDLINE (March 2016) for cross-sectional, cohort or randomised studies that measured
cognitive function in people with CKD (PROSPERO, registration number CRD42014015226). The CKD population
included people with eGFR < 60 mL/min/1.73 m2, not receiving renal replacement therapy, in any research setting.
We conducted a meta-analysis using random effects, expressed as standardised mean differences (SMD) with 95%
confidence intervals (CI). Outcomes were performance in eight cognitive domains. Bias was assessed with the
Newcastle-Ottawa Scale (NOS).
Results: We identified 44 studies reporting sufficient data for synthesis (51,575 participants). Mean NOS score for
cohort studies was 5.8/9 and for cross-sectional 5.4/10. Studies were deficient in NOS outcome and selection
due to poor methods reporting and in comparison group validity of demographics and chronic disease status.
CKD patients (eGFR < 60 mL/min/1.73 m2) performed worse than control groups (eGFR≥ 60 mL/min/1.73 m2) on
Orientation & Attention (SMD –0.79, 95% CI, –1.44 to –0.13), Language (SMD –0.63, 95% CI, –0.85 to –0.41), Concept
Formation & Reasoning (SMD –0.63, 95% CI, –1.07 to –0.18), Executive Function (SMD –0.53, 95% CI, –0.85 to –0.21),
Memory (SMD –0.48, 95% CI, –0.79 to –0.18), and Global Cognition (SMD –0.48, 95% CI, –0.72 to –0.24). Construction
& Motor Praxis and Perception were unaffected (SMD –0.29, 95% CI, –0.90 to 0.32; SMD –1.12, 95% CI, –4.35 to 2.12).
Language scores dropped with eGFR (<45 mL/min/1.73 m2 SMD –0.86, 95% CI, –1.25 to –46; 30 mL/min/1.73 m2
SMD –1.56, 95% CI, –2.27 to –0.84). Differences in Orientation & Attention were greatest at eGFR < 45 mL/min/1.73 m2
(SMD –4.62, 95% CI, –4.68 to –4.55). Concept Formation & Reasoning differences were greatest at eGFR < 45 mL/min/
1.73 m2 (SMD –4.27, 95% CI, –4.23 to –4.27). Differences in Executive Functions were greatest at eGFR < 30 mL/
min/1.73 m2 (SMD –0.54, 95% CI, –1.00 to –0.08).
Conclusions: Cognitive changes occur early in CKD, and skills decline at different rates. Orientation & Attention and
Language are particularly affected. The cognitive impact of CKD is likely to diminish patients’ capacity to engage with
healthcare decisions. An individual’s cognitive trajectory may deviate from average.
Keywords: Renal insufficiency, Chronic kidney disease, Mild cognitive impairment, Dementia, Psychometrics, Cognition,
Neuropsychological tests
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Background
Cognitive impairment is cognitive decline greater than
expected with normal ageing but which does not interfere
notably with activities of daily living. Poor cognitive func-
tion has been linked to poor health literacy, poorer medi-
cation adherence, worse physical and mental health, and
greater morbidity and mortality. Chronic kidney disease
(CKD) may be an independent risk factor for cognitive
impairment. A recent systematic review by Etgen et al. [1]
found that, in cross-sectional and longitudinal studies,
cognitive impairment and incident cognitive impairment,
respectively, were more common in CKD patients com-
pared to people without CKD. Heterogeneity between
studies was high, and age and sex were significant con-
tributors. Six cross-sectional and six longitudinal studies
could be included in their meta-analysis. While there
were few included studies, there was no evidence of pub-
lication bias, and their data suggest that lower estimated
glomerular filtration rate (eGFR) may be associated with
greater incidence of cognitive impairment [1]. Although
the economic burden of mild cognitive impairment and
CKD-related cognitive changes is poorly understood, the
cost of dementia has been studied in detail. Lower neuro-
psychological test scores are associated with increased so-
cial and financial costs, including caregiver burden [2–4].
In clinical practice, screening for or monitoring of cog-
nitive impairment relies on the use of cognitive tests.
For many clinicians, ease of use and quick administration
of cognitive tests may be particularly important. Brief
cognitive screening tests, such as the Mini-Mental State
Examination (MMSE), have been popular as a result [5].
However, general screening tools may not differentiate
specific aspects of cognition that are most affected. Cog-
nition is classified into several discrete domains, encom-
passing such diverse processes as visuo-spatial perception,
auditory memory, visual memory, attention span, motor
function, and mathematical reasoning.
The pattern of cognitive impairment in CKD is not
clear. With dialysis, CKD-related cognitive impairment is
at least partially reversible (with the domains of Orienta-
tion & Attention and Memory showing significant im-
provement), and all domains show improvement with
renal transplantation [6, 7]. It is important to understand
the pattern of cognitive impairment in CKD to distin-
guish it from neurodegenerative diseases, stroke and
traumatic brain injury, which can co-exist with CKD, may
be related to the aetiology of particular patients’ kidney
disease, and may be treatable if properly diagnosed. Un-
like CKD-related cognitive impairment, these conditions
tend to present as acute events with significant deficits
specific to the anatomy affected and which may be amen-
able to specific cognitive or occupational therapies aimed
at enhancing function rather than reversing the cause
[8–10]. CKD patients are at higher risk than the general
population for stroke, and the likelihood of stroke increases
with falling eGFR [11]. Nevertheless, CKD-related cognitive
impairment can also be severe, and patients may become
unable to make healthcare decisions [12]. Identifying the
pattern of CKD-related cognitive impairment enables two
steps toward improving care for CKD patients. Firstly,
by specifying the phenomenon under investigation, it
may bring us closer to identifying potential mechanisms,
anatomical areas affected, and treatments. Secondly, by
identifying CKD-related deficits, it may enable recom-
mendations for shared decision-making, advance care
planning, and addressing self-management challenges
related to the complex care needs of CKD patients before
their decision-making capacity diminishes.
We aimed to systematically review patterns of cognitive
impairment in CKD, specifically the cognitive domains
most affected, and to investigate any change with decli-
ning kidney function.
Methods
Protocol and registration
The study protocol was registered with the international
prospective register of systematic reviews (PROSPERO,
registration number CRD42014015226). Methodology is
reported according to Meta-analysis of Observational
Studies in Epidemiology (MOOSE) criteria.
Eligibility criteria, information sources, and search
strategies
We included all randomised controlled trials, cohort stud-
ies and cross-sectional studies where cognitive function
was measured and comparisons were possible between
non-CKD and CKD patients and/or between groups with
different stages of CKD. We did not make comparisons
with any groups on renal replacement therapy. For studies
that also had dialysis or transplant groups, only control
groups (eGFR ≥ 60 mL/min/1.73 m2) and groups with
eGFR < 60 mL/min/1.73 m2 on conservative (non-dialytic)
treatment were included in this review. Case studies, case
series, studies of children, and studies of patients currently
being treated for acute kidney injury (AKI) were excluded.
We searched MEDLINE (inception to March 2016)
using an optimally sensitive search strategy developed by
a specialist librarian (Additional file 1), without language
restriction.
Study selection, data collection, and risk of bias appraisal
Two reviewers (SW, FAD) independently screened titles
and abstracts of reports to identify potentially eligible
studies. Where necessary, full text was retrieved to deter-
mine whether a study satisfied the inclusion criteria.
Two reviewers (SW, IB) independently extracted data
from included studies using a standardised electronic
form, and disagreements were resolved through discussion.
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Where more than one publication for a study was retrieved,
reports were grouped with each report reviewed in full to
ensure inclusion of all relevant data. When repeated mea-
sures were collected, we recorded only the baseline mea-
sures to avoid measuring learning effects or effects of
treatment. We attempted to contact authors of those
studies published from 2000 to present that reported
insufficient data for meta-analysis to get more information.
We assessed risk of bias using the Newcastle-Ottawa
Scale (NOS) for cross-sectional and cohort studies [13, 14].
The NOS is a tool to assess bias in studies where each
bias-reducing criterion is used to award stars: selection
of participants (maximum of four stars for cohort and
five for cross-sectional), comparability of groups (maximum
of two stars), and measurement (maximum of three stars).
We calculated inter-rater reliability for the two reviewers
using only English-language articles, using a kappa statistic.
We also evaluated appropriateness of actual comparison
groups (not statistical adjustments) using two indicators:
demographic variables and chronic disease state. Studies
that did not report sufficient participant demographic or
disease state data were deemed inappropriately matched.
Studies with appropriate comparison groups based on
demographic variables reported similar (as defined by
p > 0.05) age, ethnicity, education, and sex (K = 1.0). Stud-
ies with appropriate comparison groups based on chronic
disease states recruited participants from similar settings
(e.g. both groups were hospitalised) and compared CKD
participants to non-CKD participants with similar chronic
disease states involving fatigue and disability (K = 0.97).
We used funnel plots to examine the risk of publication
bias.
Summary measures and synthesis of results
Multiple neuropsychological tests exist that are used to
test similar or the same aspects of cognition, thus making
analysis at the test level inadequate for examining the
pattern of cognitive impairment [15]. Two psychologists
(DP, IB) independently categorised all cognitive tests
according to widely accepted neuropsychological testing
categories; Orientation & Attention, Perception, Memory,
Language, Construction & Motor Praxis, Concept Forma-
tion & Reasoning, and Executive Functions. Ambiguities
we resolved through discussion. Tests that measured mul-
tiple domains in brief, e.g. the MMSE, were assigned to
the domain of Global Cognition.
We summarised results across cognitive domains
using a random effects model expressed as standardised
mean differences (SMD) with 95% confidence intervals
(CI). All SMDs were analysed such that lower scores
indicated poorer outcome in CKD patients (i.e. negative,
favouring non-CKD, and positive, favouring CKD). CKD
patients for the purpose of this review were defined as
non-dialysed patients with eGFR less than 60 mL/min/
1.73 m2. Stages 1 and 2 CKD (eGFR ≥ 60 mL/min/
1.73 m2) were conceptualised alongside non-CKD for ana-
lysis. Stage 3A was defined as eGFR 45–59 mL/min/
1.73 m2, 3B as eGFR 30–44 mL/min/1.73 m2, 4 as eGFR
15–29 mL/min/1.73 m2, and 5 as eGFR < 15 mL/min/
1.73 m2. In addition, we performed sub-group analyses
stratified by eGFR [16]. Where studies reported multiple
tests that mapped to the same cognitive domain, we
synthesised overall scores using a validated method to
account for the correlation among multiple tests of the
same domain, assuming an among-test correlation coeffi-
cient of 0.5 [17].
To demonstrate summary differences in absolute
terms, we multiplied SMDs by the pooled SD of the
largest study using the most common test within each
domain. This allowed the summary effect to be re-expressed
in terms of the original units of measurement of commonly
encountered tools to show how differences may be clinically
important [6].
Analyses were conducted using a combination of
Microsoft Excel for Mac 2011, Stata 13.1, and Review
Manager 5.3.
Applied subgroup and sensitivity analyses
We performed a random effects meta-regression to
explore potential effects of sex, number of tests, total
NOS scores, and NOS components (selection, compa-
rability, and outcome) on cognition. We used funnel plots
to explore potential for publication or other biases.
Results
Study selection, design and characteristics
We identified 72 eligible studies with a total of 117,858
participants (Fig. 1). Of these, 28 studies were not in-
cluded in meta-analysis due to insufficient data for synthe-
sis and inability to obtain sufficient data from authors,
despite efforts. This left 44 cross-sectional and cohort
studies with a total of 51,928 participants. Some studies
reported data for comparator subpopulations not included
in our research question (e.g. people on dialysis), so these
data were excluded, leaving data on 51,590 participants
for synthesis in final meta-analysis. We found no rando-
mised trials.
Study characteristics for studies included in the meta-
analysis are described in Table 1. See Additional file 2 for
the complete list of studies and their characteristics that
met inclusion criteria and detailed study characteristics.
The mean NOS score for cohort and cross-sectional
studies was 5.8/9 and 5.4/10, respectively (see also Add-
itional file 2 for NOS scores and demographic and health
status matching for the 44 studies that were included in the
meta-analysis). Although cohort studies performed well in
the Selection category, cross-sectional studies tended to
perform poorly. Both study types performed relatively
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poorly on Outcome, with very few providing sufficient de-
tail outcome assessment procedures. Comparability under
the NOS was high across most studies, however, examining
demographics and disease status matching of actual CKD
and comparison groups, most studies performed poorly on
both. Thus, studies were primarily limited by comparison
group validity when additional factors that may affect cog-
nition were considered. People with neurological condi-
tions (e.g. stroke) were excluded by 23 (52.3%) studies.
Cognitive tests
Cognitive domains were measured with varying frequen-
cies in synthesised studies (Table 2): Orientation & Atten-
tion (28 studies), Global Cognition (25), Memory (16),
Executive Functions (15), Construction & Motor Praxis
(11), Language (9), Concept Formation & Reasoning (6),
and Perception (1). Funnel plots for Global Cognition
tests showed some asymmetry, suggesting some studies
showing reduced differences may be missing, or have been
subject to publication bias. Funnel plots for other com-
monly tested cognitive domains were more symmetrical
(Additional file 3).
CKD patients compared to non-CKD (eGFR < 60 mL/min/
1.73 m2 vs. ≥ 60 mL/min/1.73 m2)
CKD patients (eGFR < 60 mL/min/1.73 m2) performed
more poorly than control groups (eGFR ≥ 60 mL/min/
1.73 m2) on Orientation & Attention (SMD –0.79, 95% CI,
Fig. 1 Identification and selection. PRISMA flowchart showing process
of inclusion and exclusion of studies
Table 1 Characteristics of studies included in quantitative synthesis
Characteristic Meta-analysis comparison eGFR cut point in mL/min/1.73 m2, studies (participants)
< 15 < 30 < 45 < 60 Overall
Total 6 (5482) 13 (18,041) 16 (37,259) 43 (51,418) 44 (51,575)
Region
Americas 3 (5327) 5 (8356) 8 (17,921) 21 (27,976) 22 (28,133)
Asia & Pacific 1 (60) 4 (1728) 4 (5787) 11 (9246) 11 (9246)
Europe & Russia 2 (95) 3 (7887) 4 (13,551) 8 (13,848) 8 (13,848)
Africa – 1 (70) – 3 (348) 3 (348)
Study design
Cross-sectional 6 (5482) 8 (6434) 9 (17,486) 33 (26,915) 33 (27,072)
Cohort – 5 (11,607) 7 (19,773) 10 (24,503) 10 (24,503)
Participantsa
Mean age (Range), years 67.1 (18–89)
Women 52.2%
Basis of between-groups comparisons
eGFR/proteinuria 3 11 14 31 32
CKD vs. Healthy 4 4 2 17 17
Within-CKD 1 – – – 1
CKD vs. other conditions 1 – – 1 1
aAge and sex data are taken from whole study descriptive statistics
CKD chronic kidney disease, eGFR estimated glomerular filtration rate
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–1.44 to –0.13), Language (SMD –0.63, 95% CI, –0.85 to
–0.41), Concept Formation & Reasoning (SMD –0.63,
95% CI, –1.07 to –0.18), Executive Function (SMD –0.53,
95% CI, –0.87 to –0.21), Memory (SMD –0.48, 95% CI,
–0.79 to –0.18), and Global Cognition (SMD –0.48, 95%
CI, –0.72 to –0.24) tests (Figs. 2 and 3). Studies were
limited primarily by comparison group validity, with very
few being appropriately matched for demographics or
health status.
Stratified comparisons by CKD stage
Figure 2 demonstrates changes in cognition by CKD
stage, by comparing SMD above and below CKD stage
eGFR cut points. Although Language scores continued
to drop with lower eGFR (< 45 mL/min/1.73 m2, Stages
4, 3B, and non-dialysed CKD Stage 5 vs. Stage 3A and
better, SMD –0.86, 95% CI, –1.25 to –46; 30 mL/min/
1.73 m2, Stage 4 and non-dialysed Stage 5 vs. Stage 3B
and better, SMD –1.56, 95% CI, –2.27 to –0.84), this
was not the case for all domains (Fig. 3). Differences in
Orientation & Attention were most apparent in patients
with eGFR < 45 mL/min/1.73 m2 (Stages 4, 3B, and non-
dialysed CKD Stage 5 vs. Stage 3A and better; SMD –
4.62, CI –4.68 to –4.55). One large study also demon-
strated that Concept Formation & Reasoning differences
were most apparent at eGFR < 45 mL/min/1.73 m2
(Stages 4, 3B, and non-dialysed CKD Stage 5 vs. Stage
3A and better SMD –4.27, 95% CI, –4.23 to –4.27).
Differences in Executive Functions were most apparent at
eGFR < 30 mL/min/1.73 m2 (Stage 4 and non-dialysed
CKD Stage 5 vs. Stage 3B and better, SMD –0.54, 95% CI,
–1.00 to –0.08). Construction & Motor Praxis was un-
affected by CKD at any stage (eGFR < 60 mL/min/1.73 m2
vs. ≥ 60 mL/min/1.73 m2 SMD –0.29, 95% CI, –0.90 to
0.32), and Perception (which was measured by one small
study) also appeared to be unaffected (eGFR < 60 mL/min/
Table 2 Cognitive domains of synthesised studies, including subdomains
Cognitive domain
(Studies)
Sub-domains (Studies) Description of domain Examples
Orientation &
Attention (28)
Orientation (0) Ability to attend to one’s environment and
maintain short-term or continuous focus on
information or tasks
Trail Making Test, digit span, digit-symbol
substitution, immediate recall
Attention, processing speed,
and working memory (28)
Perception (1) Visual (0) Ability to receive and make sense of stimuli Hooper Visual Organization, Halstead-Reitan
speech sounds perception test
Auditory (1)
Tactile (1)
Olfactory (0)
Memory (17) Verbal (16) Ability to remember information, whether
verbal, auditory, or visual following a
period of time
California Verbal Learning Test, Wechsler
Memory Scale, facial memory,
visual memory, word list, long delay recallVisual (4)
Tactile (0)
Incidental learning (0)
Prospective learning (0)
Remote memory (0)
Language (9) Aphasia (3) Ability to understand, produce, and use
language appropriately
Boston Naming Test
Verbal expression (4)
Verbal comprehension (3)
Verbal academic skills (0)
Construction &
Motor Praxis (11)
Drawing (4) Ability to produce or orient within space
2D or 3D representations
Rey-Osterreith Complex Figure, Wechsler
Adult Intelligence Scale block design and
object assembly tests, Purdue PegboardAssembling and building (4)
Motor skills (3)
Concept Formation
& Reasoning (6)
Concept formation (2) Ability to utilise patterns and abstract
concepts to solve problems
Judgment of Line Orientation, Raven’s
Progressive Matrices
Reasoning (4)
Mathematical procedures (0)
Executive Functions (15) ‘Higher order’ abilities that draw on multiple
other domains
Wisconsin Card Sorting Test, verbal fluency
Global Cognition (25) Collection of domains measured in cognitive
impairment (e.g. dementia and Alzheimer’s disease)
screening tests; these primarily measure Orientation
& Attention, Memory, and Language
MMSE, Modified MMSE (3MS), Telephone
Interview for Cognitive status
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1.73 m2 vs. ≥ 60 mL/min/1.73 m2 SMD –1.12, 95% CI,
–4.35 to 2.12). Figure 4 shows estimated changes in test
scores for commonly used tests in the domains of Orien-
tation & Attention, Language, and Global Cognition.
Applied subgroup and sensitivity analyses
No differences in cognitive test scores were observed
based on sex, number of tests applied, NOS total scores,
or NOS component scores (Fig. 5).
Discussion
We found cognitive changes occur early in CKD, and that
these changes progress at different rates for different cog-
nitive domains as CKD progresses and eGFR declines.
This finding confirms and expands on both the trend
suggested by Etgen et al.'s [1] meta-analysis that risk of
cognitive impairment increases with lower eGFR and
that, overall, CKD patients have poorer cognition than
those without CKD. Our data, however, examined per-
formance in individual cognitive domains rather than
incidence, thus characterising the cognitive impairment.
CKD patients performed worse than control groups on
Orientation & Attention, Language, Concept Formation &
Reasoning, Memory, Executive Function, and Global
Cognition tests. The early effect of CKD on Orientation &
Attention may have a knock-on effect to other cognitive
domains such as Memory. This would be consistent with
symptoms reported by patients, such as a general cogni-
tive ‘slowness’ or ‘haziness’ that may be associated with
word finding difficulties or trouble following logical argu-
ments. Each domain followed a unique pattern of decline,
with some such as language continuing to decline and
Fig. 2 Standardised mean differences in cognitive domains within estimated glomerular filtration rate cut point groups
Fig. 3 Standardised mean differences in cognitive scores comparing participants at estimated glomerular filtration rate cut points
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others plateauing or only becoming problematic at a
certain point. As this review excluded studies of AKI
patients, it would be inappropriate to draw conclusions
about the trajectory of AKI patients, including AKI in the
context of CKD. The trajectory of CKD-related cognitive
impairment does not appear to manifest as a rapid decline,
as demonstrated by shifts across CKD stages which typi-
cally occur over years. Such a clinical scenario involving
rapid deterioration in cognitive function would necessitate
evaluation for delirium, sepsis, AKI, stroke, traumatic
brain injury, and other clinically indicated differential
diagnoses.
Applicability of findings in clinical practice
Although there may be overlap in some of the deficits in
severe CKD-related cognitive impairment, the pattern of
cognitive impairment evident in CKD patients does not
follow that of any known dementia syndrome nor trau-
matic brain injury. There is thus a lack of fit with exist-
ing services designed for cognitive impairment in adults
Fig. 4 Estimated mean differences in test scores for commonly used tests
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and a lack of guidelines for addressing CKD patients’
cognition-related needs. Given the potential for cognitive
impairment, CKD patients may need assistance navigating
care pathways, weighing up treatment options, compiling
advice from multiple sources, maintaining medication
regimens, and remembering appointments and pharmacy
pick ups. Thus, early liaison with multidisciplinary neph-
rology and community services to support patient inde-
pendence and coordination with all providers may be an
important step in the care of patients as they navigate the
progression of their CKD.
Even as eGFR fell below 60 mL/min/1.73 m2, using
our cross-sectional meta-analytic design, early impair-
ment was seen in the areas of Orientation & Attention,
Language, Concept Formation & Reasoning, Memory, and
Executive Functions. Differences in mean scores could
also be detected on Global Cognition screening tests.
Although scores on individual tests may not, at this point,
fall below standardised cut off points for cognitive impair-
ment, it may be important for clinicians to track patient
cognition over time from baseline and for patients to
know that changes they experience are probably due
to kidney disease rather than age or mental illness.
As cognitive impairment can be severe by CKD stages
4 and 5, a patient’s capacity to make healthcare decisions
can be greatly diminished [12]. Health literacy refers to
“the wide range of skills, and competencies that people
develop to seek out, comprehend, evaluate and use health
information and concepts to make informed choices,
reduce health risks and increase quality of life” [18]. It
is one aspect of health decision-making, and although
low literacy is associated with low health literacy, the
two are not interchangeable [19]. Even before capacity is
diminished, basic health literacy may be affected through
mechanisms such as poor attention and memory as well
as reduced language and reasoning skills. The link be-
tween poor health literacy and outcomes is well estab-
lished, and clinicians can work to support health literacy
in CKD patients to improve quality of care [20–24]. There
is a clear need for resources that accommodate CKD-
related cognitive impairment, and knowledge measures
have been shown useful in other populations to gauge
usefulness of such aids [25]. By screening CKD patients
for impaired Orientation & Attention using tools such as
the Trail Making Test B, early identification of difficulties
may lead to targeted interventions and early discussions
with the patient and their family.
Strengths and limitations of the current study
A strength of our work is the pragmatic and systematic
approach to summarising cognitive impairment in CKD
from a broad reaching neuropsychological perspective. It
is important to acknowledge that we have synthesised
the average effects that have been observed and that the
cognitive trajectory of an individual may deviate from
the average effect. Similarly, where we have shown a dis-
tinct pattern of cognitive change associated with CKD,
dementia is common in older patients and thus may
coexist within an individual. It should be noted that these
patterns were identified through the analysis of cross-
sectional data and not longitudinal data. A given person
may not exhibit a particular pattern of cognitive impair-
ment, but we see that, for a given eGFR in a person with
CKD, certain deficits may be expected.
Although most studies controlled for at least two demo-
graphic variables (age, education and sex were common),
Fig. 5 Subgroup sensitivity analyses. Subgroup sensitivity analyses showed no differences based on sex, number of cognitive tests, NOS total
score, or NOS components
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many factors are associated with differences in cognitive
testing scores. Studies were limited primarily by compari-
son group validity, with very few being well matched for
demographics and health status. As a result, the degree of
cognitive impairment in CKD patients may be biased.
Consensus on a standardised test battery, given the pat-
terns of deficit we have observed, would make comparison
of studies and subgroups clearer and has recently been
identified as a research priority [26]. Future research
should aim to test well matched CKD and control groups
across a range of cognitive domains and compare stages of
CKD. Additionally, more research is needed examining
the domain of Perception in CKD to provide more defini-
tive results.
Conclusions
CKD affects several cognitive domains but not predomin-
antly those associated with dementia syndromes. Domains
particularly affected are Orientation & Attention and
Concept Formation & Reasoning, while other domains
affected include Memory, Language, and Executive Func-
tions. Global Cognition measures appear to be useful in
screening for CKD-related cognitive impairment but may
not correlate well with renal function. More research
comparing CKD patients with well matched non-CKD
patients would improve understanding of CKD-related
cognitive impairment.
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